Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 3/20 | 0.36 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL104721 | 1.00 | CA1 (0.43) | CA1CA9BBOX1CA4FAHD1 | |
| Fumaric Acid SCHEMBL105086 | 1.00 | CA1 (0.43) | CA1CA9BBOX1CA4FAHD1 | |
| Fumaric Acid SCHEMBL31550455 | 1.00 | CA1 (0.43) | CA1CA9BBOX1CA4FAHD1 | |
| Fumaric Acid SCHEMBL106908 | 0.96 | — | — | |
| Fumaric Acid SCHEMBL107533 | 0.96 | — | — | |
| Fumaric Acid SCHEMBL21815723 | 0.95 | CA1 (0.45) | CA1CA9BBOX1CA4FAHD1 | |
| Fumaric Acid SCHEMBL6553031 | 0.95 | CA1 (0.45) | CA1CA9BBOX1CA4FAHD1 | |
| Fumaric Acid SCHEMBL6553020 | 0.95 | CA1 (0.45) | CA1CA9BBOX1CA4FAHD1 | |
| Fumaric Acid SCHEMBL23828619 | 0.91 | — | — | |
| Fumaric Acid SCHEMBL21815644 | 0.91 | CA1 (0.43) | CA1CA9BBOX1CA4FAHD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 648 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097044-A1 | ION PAIR LIQUID CRYSTAL FORMULATIONS FOR LONG-ACTING INJECTABLES OF POORLY SOLUBLE DRUGS | FORDOZ PHARMA CORP. (US) | 2026-04-09 | — | — | US | claimed |
| EP-3825278-B1 | METHOD FOR PREPARING HIGH-PURITY BISFLUOROSULFONYLIMIDE SALT | SHANGHAI ROLECHEM CO LTD (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250273682-A1 | BINDER FOR ELECTRICITY STORAGE DEVICE, BINDER SOLUTION FOR ELECTRICITY STORAGE DEVICE, ELECTRODE SLURRY FOR ELECTRICITY STORAGE DEVICE, ELECTRODE FOR ELECTRICITY STORAGE DEVICE, AND ELECTRICITY STORAGE DEVICE | KURARAY CO., LTD. (JP) | 2025-08-28 | — | — | US | claimed |
| US-20250197778-A1 | STORAGE STABILIZATION AGENT FOR AQUEOUS HOME CARE FORMULATIONS | OMYA INTERNATIONAL AG (CH) | 2025-06-19 | — | — | US | claimed |
| EP-4540357-A1 | STORAGE STABILIZATION AGENT FOR AQUEOUS HOME CARE FORMULATIONS | Omya International AG (CH) | 2025-04-23 | — | — | EP | claimed |
| CN-119684502-A | Multifunctional adhesive, preparation method and application thereof | 华中科技大学 | 2025-03-25 | — | — | CN | claimed |
| US-20250087693-A1 | CATHODE ELECTRODE SHEET, A PREPARATION METHOD THEREOF AND A LITHIUM-ION BATTERY COMPRISING SAME | MURATA MANUFACTURING CO., LTD. (JP) | 2025-03-13 | — | — | US | claimed |
| CN-119601663-A | Positive electrode plate, preparation method thereof and lithium ion battery comprising positive electrode plate | 株式会社村田制作所 | 2025-03-11 | — | — | CN | claimed |
| CN-119505762-A | Polyacrylic acid binder, preparation method thereof and lithium ion battery | 万华化学集团电池科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119462713-A | Preparation method of lithium fluoroborate salt containing unsaturated bond | 多氟多新材料股份有限公司 | 2025-02-18 | — | — | CN | claimed |
| EP-1478339-B1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORP (US) | 2008-06-04 | — | — | EP | claimed |
| EP-1838307-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2007-10-03 | — | — | EP | claimed |
| WO-2006060464-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060122162-A1 | Methods of using temozolomide formulation intrathecally in the treatment of cancers | SCHERING CORPORATION | 2006-06-08 | — | — | US | claimed |
| US-6987108-B2 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION (US) | 2006-01-17 | — | — | US | claimed |
| EP-1478339-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION | 2004-03-04 | — | — | US | claimed |
| WO-2003072082-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2003-09-04 | — | — | WO | claimed |
| US-4040970-A | WITH COPOLYMER FOR RENDERING THE TONER NEGATIVELY CHARGEABLE | CANON KABUSHIKI KAISHA (JA) | 1977-08-09 | — | — | US | claimed |
| US-3977983-A | Liquid developer for use in development of an electrostatic latent image comprising a copolymer containing an amino group converted into a quaternary ammonium salt or hydroxide | CANON KABUSHIKI KAISHA (JA) | 1976-08-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | ASNS, TP53, QPCTL | CA1 924/4885CA9 1993/4885BBOX1 3869/4885 |
| US-20260097044-A1 | ION PAIR LIQUID CRYSTAL FORMULATIONS FOR LONG-ACTING INJECTABLES OF POORLY SOLUBLE DRUGS | SSB, LTB4R2, THRB | CA1 1539/4885CA9 2955/4885BBOX1 3285/4885 |
| US-20060122162-A1 | Methods of using temozolomide formulation intrathecally in the treatment of cancers | PMP22, TUBB2A, TUBB6 | CA1 49/4885CA9 250/4885BBOX1 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.